The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.82
Bid: 3.70
Ask: 3.94
Change: 0.01 (0.26%)
Spread: 0.24 (6.486%)
Open: 3.81
High: 0.00
Low: 0.00
Prev. Close: 3.81
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

29 Jan 2016 07:00

RNS Number : 3769N
Plant Health Care PLC
29 January 2016
 

 

 

PLANT HEALTH CARE plc

 

("Plant Health Care" or the "Company")

 

 

Trading Update

 

Plant Health Care, a leading provider of novel patent-protected biological products to the global agriculture markets, issues the following post year-end trading update ahead of the announcement of the Company's audited full year financial results for the year ended 31st December 2015, which is expected no later than the first week of April. All results provided are preliminary and subject to completion of the 2015 audit.

 

The Company is pleased to report strong financial performance in FY2015 in line with expectations. Progress with our Plant Response Elicitor technology ("PREtec") platform has accelerated.

 

Financial and Commercial Highlights

- Revenue of approximately $7.5m; growth year over year at constant currency was 15%; 9% growth in US$, largely due to the weakness of the Mexican peso

- Sales of the core Harpin products increased by 22%, driven by strong sales in the United States and Europe; Harpin and Myconate® products represented 57% of sales in 2015 (2014: 53%)

- Gross Margin increased to 62% in 2015 from 51% in 2014

- Cash and cash equivalents at 31st December 2015 were $8.4m

- Revenue growth in Mexico of approximately 14% in local currency

- In conjunction with a significant increase in R&D investment to $5.7m in 2015, the overall operating result was a loss of approximately $7.3m in 2015 as compared to $6.1m in 2014

- A roughly two-fold increase in sales to Sym-Agro, a key partner in the Pacific North West

- Achieved the Company's first product registration in Brazil; now preparing for a launch in sugar cane

 

PREtec Highlights

- Signed four evaluation agreements with major players in the agriculture industry for our first family of PREtec peptides, Innatus 3G

- Completed third year of field trials in corn with Innatus 3G, including one peptide variant with three years of field trial data delivering an average yield increase of 9.6 bushels per acre when applied as a seed treatment compared with industry standard treatments alone, with a win rate of 79%, with data from 19 of 20 sites analyzed to date

- Very promising early results on additional peptide families beyond Innatus 3G

- Significantly strengthened the R&D team in Seattle and our licensing capability; moved into expanded laboratories in 3Q

 

Paul Schmidt, CEO, commented:

"2015 was a pivotal year for Plant Health Care. We made substantial progress in growing our commercial business and advancing our PREtec platform.

We are engaging actively with our evaluation partners for Innatus 3G, our first PREtec peptide family, and are encouraged by positive early results. Field and laboratory trials continue and are anticipated to further reinforce the initial promise of this family.

 

Our expanded research team in Seattle is making rapid strides, and we are very encouraged by the early results of studies on other peptide families beyond Innatus 3G. We intend to continue to evaluate and advance these additional peptide families and anticipate presenting at least one new family to potential partners during 2016.

On the commercial side, sales of Harpin αβ continued to grow; we have recorded 22% CAGR from 2012 to 2015, excluding license payments. This is despite strong headwinds in the agriculture industry due to low commodity prices. Increased demand for both Harpin αβ and Myconate in specialty crops has led to strong sales growth in our Mexico subsidiary as well as via Sym-Agro in the Pacific North West. In Brazil, our partner is conducting a further year of trials in sugar cane, prior to its anticipated launch of Harpin αβ.

 

This is an exciting time for Plant Health Care. We are advancing in line with our strategy and confident in our future direction."

 

 

For further information, please contact:

 

Plant Health Care plc

Paul Schmidt, Chief Executive Officer Tel: +1 919 926 1600

Jeffrey Hovey, Chief Financial Officer

 

Liberum Capital - Nomad and Broker

Clayton Bush / Chris Clarke Tel: +44 (0) 20 3100 2000

 

LHA

Ed McGregor / Jody Burfening Tel: +1 (212) 838 3777

 

Company website: www.planthealthcare.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTLFFVILSITFIR
Date   Source Headline
30th Oct 20147:00 amRNSPHC & Sipcam Enter Agreement
27th Oct 20147:00 amRNS3G Peptide Technology Platform shows major promise
23rd Oct 20144:29 pmRNSHolding(s) in Company
6th Oct 201411:25 amRNSDirector/PDMR Shareholding
2nd Oct 20147:00 amRNSDirector/PDMR Shareholding
15th Sep 20147:00 amRNSHalf Yearly Report
19th Aug 201410:28 amRNSAIM Blocklisting Return
12th Aug 20143:10 pmRNSTR-1 Notification of Major Interest in Shares
22nd Jul 20144:10 pmRNSTR-1 Notification of Major Interest in Shares
30th Jun 20149:18 amRNSTotal Voting Rights
5th Jun 201412:45 pmRNSTR-1 Notification of Major Interest in Shares
22nd May 20147:00 amRNSDelisting of shares from the CISX
8th May 20141:30 pmRNSAGM Voting Results
15th Apr 201411:30 amRNSDirector/PDMR Shareholding
15th Apr 20147:00 amRNSDirector/PDMR Shareholding
9th Apr 20142:15 pmRNSDirector's Dealing - Grant of Share Options
9th Apr 20142:00 pmRNSTR-1 Notification of Major Interest in Shares
7th Apr 20145:15 pmRNSPublication of Annual Report 2013 & Notice of AGM
31st Mar 20143:45 pmRNSTotal Voting Rights
24th Mar 20147:00 amRNSPreliminary Results
3rd Mar 20144:35 pmRNSPrice Monitoring Extension
28th Feb 20141:00 pmRNSTotal Voting Rights
19th Feb 201412:15 pmRNSBlocklisting Interim Review
17th Feb 20149:45 amRNSTR-1 Notification of Major Interest in Shares
6th Feb 20144:40 pmRNSSecond Price Monitoring Extn
6th Feb 20144:35 pmRNSPrice Monitoring Extension
31st Jan 20143:00 pmRNSTotal Voting Rights
15th Jan 20147:00 amRNSTrading Statement
29th Nov 201312:12 pmRNSDirector's Shareholding
25th Nov 20133:15 pmRNSDivestment of non-core subsidiary
18th Oct 20135:00 pmRNSTR-1 Notification of Major Interest in Shares
30th Sep 20135:00 pmRNSTotal Voting Rights
23rd Sep 201310:30 amRNSDirector/PDMR Shareholding
19th Sep 20137:00 amRNSAppointment of Adviser
18th Sep 20133:15 pmRNSDirector/PDMR Shareholding
16th Sep 20137:03 amRNSDirectorate Change
16th Sep 20137:00 amRNSHalf Yearly Report
19th Aug 20132:30 pmRNSBlocklisting Interim Review
30th Jul 20137:01 amRNSUpdate on Harpin
30th Jul 20137:00 amRNSPHC announces plans for Harpin seed treatment
22nd Jul 201311:00 amRNSPHC hires Glen Donald as VP Business Development
19th Jul 20137:00 amRNSHead Office Relocation,Research Facility Expansion
15th Jul 20135:15 pmRNSDirector/PDMR Shareholding
5th Jul 20137:00 amRNSUpdate on CISX Listing
3rd Jul 20137:00 amRNSNew Long-Term Incentive Plan and Grant of Awards
7th Jun 20134:15 pmRNSDirectorate Change
31st May 201311:30 amRNSTotal Voting Rights
21st May 201312:00 pmRNSHarpin Granted Federal Registration in Mexico
10th May 20134:45 pmRNSDirector/PDMR Shareholding
9th May 20131:20 pmRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.